Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 4/20 | 0.58 |
| ▸ | LMNA | P02545 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | TACR3 | P29371 | 1/20 | 0.47 |
| ▸ | HSD17B2 | P37059 | 3/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.44 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.44 |
| ▸ | HPGDS | O60760 | 2/20 | 0.44 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9569932 | 0.87 | ADORA2A (0.58) | EGFRLMNAALDH1A1TACR3ADORA2A | |
| SCHEMBL7256231 | 0.82 | TACR3 (0.53) | EGFRLMNAALDH1A1SMN1; SMN2TACR3 | |
| SCHEMBL21676260 | 0.80 | EGFR (0.54) | EGFRALDH1A1ADORA2AADORA1MAPT | |
| SCHEMBL17670900 | 0.77 | TACR3 (0.47) | LMNAALDH1A1TACR3HSD17B2ADORA2A | |
| SCHEMBL2472432 | 0.77 | EGFR (0.50) | EGFRLMNAALDH1A1ADORA2AADORA1 | |
| SCHEMBL3387703 | 0.77 | EGFR (0.50) | EGFRLMNAALDH1A1ADORA2AADORA1 | |
| SCHEMBL5438509 | 0.75 | MEN1 (0.51) | EGFRALDH1A1SMN1; SMN2RXFP1HTT | |
| SCHEMBL6988044 | 0.75 | EGFR (0.58) | EGFRLMNAALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL14469060 | 0.75 | EGFR (0.57) | EGFRLMNAALDH1A1SMN1; SMN2 | |
| SCHEMBL701920 | 0.74 | TAS1R3 (0.48) | EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030195212-A1 | Novel melanocortin receptor agonists and antagonists | MELACURE THERAPEUTICS AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1254114-A2 | MELANOCORTIN RECEPTOR AGONISTS AND ANTAGONISTS | Melacure Therapeutics AB (SE) | 2002-11-06 | — | — | EP | claimed |
| WO-2001055106-A2 | NOVEL MELANOCORTIN RECEPTOR AGONISTS AND ANTAGONISTS | MELACURE THERAPEUTICS AB (SE) | 2001-08-02 | — | — | WO | claimed |
| EP-1254114-A2 | MELANOCORTIN RECEPTOR AGONISTS AND ANTAGONISTS | Melacure Therapeutics AB (SE) | 2002-11-06 | — | — | EP | disclosed |
| WO-2001055106-A2 | NOVEL MELANOCORTIN RECEPTOR AGONISTS AND ANTAGONISTS | MELACURE THERAPEUTICS AB (SE) | 2001-08-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195212-A1 | Novel melanocortin receptor agonists and antagonists | MC1R, MC5R, MC4R | EGFR 909/4885LMNA 4570/4885ALDH1A1 2823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.